The first 100 Days of the Trump Administration are behind us. For all the flurry of activity and tremendous market volatility ...

JEPQ's covered call approach thrives on market uncertainty, offering strong income and tech exposure with momentum upside.

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could ...

Legend Biotech faces a 60% stock drop amid safety, supply issues, and competition for its CAR-T therapy, Carvykti. See here ...

Nasdaq Inc. closed 7.09% short of its 52-week high of $84.15, which the company reached on February 6th.

Strategists at BNP Paribas have conducted another deep-dive into the past 100 years of equity-market crashes—and they’re now ...

This article compares the JEPI and JEPQ ETFs and assesses the better one to buy for long term gains and yields.

The S&P 500 nearly fully recovered from early-April tariff-induced losses, ending April with a 2% decline. Click here to read ...

The S&P 500 (SP500) has put in its worst performance for the first 100 days of any U.S. presidency since 1973. Read more here ...

Overall, AMD's growth story is very imbalanced. Its flywheel is revving full speed ahead in AI and data centers, with old ...

GPIQ charges a low expense ratio (versus peers), but it's lower fee versus QYLD is likely attributable to lower covered call ...

GPIQ's flexible strategy and selective covered-call approach have enabled it to outperform peers. Read why I upgrade the fund ...